Pre/post analysis for bundle trusts.

<p>¹ P-value refers to difference of this trend from zero</p><p>² P-values refer to difference between this trend and pre-implementation trend</p><p>Pre/post analysis for bundle trusts.</p

Pre/post analysis for bundle trusts.

<p>¹ P-value refers to difference of this trend from zero</p><p>² P-values refer to difference between this trend and pre-implementation trend</p><p>Pre/post analysis for bundle trusts.</p

28 day readmissions in bundle trusts and London comparison group.

<p>28 day readmissions in bundle trusts and London comparison group.</p

Implementation dates of COPD care bundle.

<p>* Subsequently changed to Croydon Health Services NHS Trust</p><p>** Merged to become Whittington Health from April 2011</p><p>Implementation dates of COPD care bundle.</p

Bundle trusts vs. other trusts nationally for COPD admissions.

<p>¹ P-value refers to difference of this trend from zero</p><p>² P-values refer to difference between these trends and the trend in national comparison trusts</p><p>³ P-value refers to difference between this trend and trend in national comparison trusts, adjusted for baseline trends</p><p>Bundle trusts vs. other trusts nationally for COPD admissions.</p

Change in levels of fractalkine in BAL cells following <i>in vitro</i> infection with RV16 and RV1B.

<p>Soluble fractalkine protein was measured in cell supernatants from BAL cells obtained from (A) non-asthmatic (n = 15) and (B) asthmatic (n = 15) subjects and compared between subject groups at 8hrs post infection (C). Fractalkine mRNA expression was measured in BAL cell lysate cDNA obtained from non-asthmatic (D) and asthmatic (E) subjects. The results are expressed as mean ± SEM. Protein data were analysed by one-way ANOVA with Bonferroni post-test and mRNA by Kruskal Wallis with Dunn’s post test (**<i>P</i><0.01).</p

Change in soluble fractalkine in BAL fluid during experimental <i>in vivo</i> RV16 infection, related with upper respiratory symptom scores.

<p>Soluble fractalkine protein was measured in filtered BAL fluid collected at baseline and day 4 post RV16 infection from non-asthmatic (n = 10), mild-asthmatic (n = 11) and moderate-asthmatic (n = 14) subjects. (A) Data is presented as soluble fractalkine (pg/mL) per subject and horizontal bars for median levels for each group in BAL fluid obtained at baseline and day 4. Data were analysed within groups by Wilcoxon-matched pairs signed rank tests and between groups by Mann Whitney U test, *P<0.05. (B) Levels of fractalkine in BAL fluid on Day 4 were correlated with peak upper respiratory symptom scores for each subject infected using Pearson’s correlation (r = 0.289, <i>P</i> = 0.098).</p

Change in levels of fractalkine in PBMCs following <i>in vitro</i> infection with RV16 and RV1B.

<p>Soluble fractalkine protein was measured in cell supernatants from PBMCs obtained from (A) non-asthmatic (n = 15) and (B) asthmatic (n = 15) subjects and compared between subject groups at 8hrs post infection (C). Fractalkine mRNA expression was measured in PBMC cell lysate cDNA obtained from (D) non-asthmatic and (E) asthmatic subjects. The results are expressed as mean ± SEM. Protein data were analysed by one-way ANOVA with Bonferroni post-test and mRNA by Kruskal Wallis with Dunn’s post test (*<i>P</i><0.05, ***<i>P</i><0.001).</p